Clinical trial · Observational
Decisions of Young Women With Breast Cancer Regarding Fertility Preservation Before Cancer Treatment and Family Building After Treatment
NCT03817814CI-TRIAL-00093761completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will help the researchers learn more about factors that affect the decisions about fertility preservation and family building made by young women with breast cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Fertility Preservation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| web-based questionnaire | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Women with Breast Cancer
- description
- This is a cross-sectional survey of young women with breast cancer (YWBC) who received a consultation with an MSK Fertility Nurse Specialist before starting cancer treatment.
- interventionNames
- Behavioral: web-based questionnaire
Primary outcomes (1)
- measure
- Patient-reported outcome questionnaire - Fertility Preservation Questionnaire
- timeFrame
- 1 year
- description
- Number of patients reporting that fertility tools were recommended to them following their breast cancer diagnosis
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Breast cancer, Stage 0-III * Female * 18-45 years of age at time of diagnosis * Patients that completed their primary breast cancer treatment (surgery, chemotherapy, radiation therapy). Patients can still be on endocrine therapy, trastuzumab and/or pertuzumab therapy. * Received education and counseling by MSK Fertility Nurse Specialist before beginning cancer treatment from 2009 through 2018 Exclusion Criteria: * Unable to read English
References
Publications (0)
Data not yet available
No reference posted for this study.